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Abstract: Methamphetamine is, worldwide, one of the most consumed drugs of abuse. One important
side effect is neurodegeneration leading to a decrease in life expectancy. The aim of this paper was to
check whether the drug affects one of the receptors involved in neurodegeneration/neuroprotection
events, namely the adenosine A2A receptor (A2AR). First, we noticed that methamphetamine does not
affect A2A functionality if the receptor is expressed in a heterologous system. However, A2AR becomes
sensitive to the drug upon complexes formation with the cannabinoid CB1 receptor (CB1R) and the
sigma 1 receptor (σ1R). Signaling via both adenosine A2AR and cannabinoid CB1R was affected
by methamphetamine in cells co-expressing the two receptors. In striatal primary cultures, the
A2AR–CB1R heteromer complex was detected and methamphetamine not only altered its expression
but completely blocked the A2AR- and the CB1R-mediated activation of the mitogen activated protein
kinase (MAPK) pathway. In conclusion, methamphetamine, with the participation of σ1R, alters
the expression and function of two interacting receptors, A2AR, which is a therapeutic target for
neuroprotection, and CB1R, which is the most abundant G protein-coupled receptor (GPCR) in
the brain.
Keywords: G protein-coupled receptor GPCR; striatal neurons; heteromer; drug of abuse; neuropro-
tection
1. Introduction
Methamphetamine is one of the most consumed drugs of abuse in developed countries.
It causes significant health and socio-economic problems that impact on sufferers, families,
and the civil Society as a whole. Cocaine and methamphetamine share their ability to
increase the brain levels of one of the main neurotransmitters, dopamine. Seemingly, the
two drugs share some of the mechanisms that lead to addiction, but they also display
differential trends.
Five dopamine receptors have been identified so far: D1, D2, D3, D4 and D5. They
belong to the superfamily of G protein-coupled receptor (GPCRs) and, in mammals, they
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are expressed in neural cells but also in many other cell types. In the central nervous
system, these receptors mediate the effects of dopamine in almost any higher function: from
cognition to motor control. Plastic changes affecting the expression of dopamine receptors
in the neurons of the reward circuits are concomitant with drug addiction and relapse.
Dopamine action is counterbalanced by adenosine, a neuromodulator whose receptors, A1,
A2A, A2B and A3, in addition to being GPCRs, are widely distributed in the central nervous
system (CNS). Among adenosine receptors, A2A is arising as a target for neuroprotection.
There are several studies, both in vitro and in animal models of neurodegenerative diseases,
that show that antagonists of this receptor have neuroprotective potential. These results
add to the epidemiological finding that natural antagonists of adenosine receptors, such
as caffeine, theophylline or theobromine, reduce the risk of suffering from Parkinson’s or
Alzheimer’s diseases [1–9].
In the basal ganglia, dopamine and adenosine receptors interact to form functional
complexes. Interestingly, we have previously discovered a functional complex that me-
diates the motor effects of cannabinoids formed by A2A, D2 and a cannabinoid receptor,
CB1 [10–12]. Endocannabinoids are neuromodulators acting on two GPCRs, cannabinoid
CB1 and CB2 receptors (CB1R and CB2R), which are expressed in different systems of the
mammalian body. Some effects of natural phytocannabinoids are mediated by these recep-
tors, that are differentially expressed in the CNS: the CB1 is more abundant in neurons and
the CB2 is more abundant in non-neuronal cells. Although trans(-)∆9-tetrahydrocannabinol
(∆9-THC), the most well-known compound of Cannabis sativa, has psychotropic effects,
its potential to induce addiction is controversial. Accordingly, the role of cannabinoid
receptors in addiction is not well understood.
Relevant for this project was (i) the discovery that ∆9-THC blocks methamphetamine-
induced neurotoxicity [13,14] and (ii) the recent discovery that an allosteric modulator of
the CB1R, cannabidiol [15], suppresses the cognitive effect of ∆9-THC via the A2A/CB1
receptor heteromer [16].
It is known that, to exert some of its noxious effects, cocaine binds to the sigma 1
receptor (σ1R), which does not belong to the GPCR family and has no known endoge-
nous agonist [17–21]. Intriguingly, methamphetamine alters the functionality of the σ1R,
although the underlying mechanism remains obscure [22–26]. The aim of this paper was
to investigate whether methamphetamine, in a σ1R-dependent or -independent fashion,
was able to alter the interaction and functionality of the heteromer formed by A2A and CB1
receptors (A2A–CB1Het) in both a heterologous expression system and primary cultures of
striatal neurons.
2. Results
2.1. Methamphetamine Does Not Disrupt the Formation of A2A and CB1 Receptor Complexes in a
Heterologous Expression System
The effect of methamphetamine on receptor expression was first assessed in trans-
fected HEK-293T cells. Immunocytochemistry assays showed that the membrane expres-
sion level of CB1R was not altered when cells were pre-treated for 1 h with metham-
phetamine (1 µM) (Figure 1A,D). Similar results were observed in HEK-293T cells express-
ing A2AR (Figure 1B,E). When analyzing HEK-293T cells expressing equal amounts of
CB1R and A2AR, the two receptors colocalized at the plasma membrane level (yellow in
Figure 1C) and methamphetamine pretreatment did not induce any significant change in
colocalization (Figure 1F).
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Figure 1. The effect of methamphetamine on A2AR–CB1R colocalization and receptor–receptor interaction. Confocal mi-
croscopy images were obtained in HEK-293T cells transfected with 0.5 μg cDNA coding for CB1R-YFP (A,D), with 0.5 μg 
cDNA for A2AR-Rluc (B,E) or with 0.5 μg cDNA for both CB1R-YFP and A2AR-Rluc (C,F). Cells were treated with 1 μM 
methamphetamine (D–F) or vehicle (A–C) for 1 h. Receptors fused to Rluc (red) were identified by immunocytochemistry 
and receptors fused to YFP (green) were identified by their own fluorescence. Colocalization is shown in yellow. Nuclei 
were stained with Hoechst (blue). Images are taken near the surface of the slide to observe a higher portion of the plasma 
membrane. Scale bars: 20 μm. (G): Bioluminescence Resonance Energy Transfer (BRET) assays were performed in HEK-
293T cells transfected with a constant amount of the cDNA coding for A2AR fused to Rluc (1 μg) or the cDNA coding for 
D1R fused to Rluc (0.5 μg to 4.5 μg) (red line) and increasing amounts of the cDNA coding for CB1R fused to YFP (0.5 μg 
to 4.5 μg). Transfected cells were treated (green dots) or not (blue dots) with 1 μM methamphetamine. BRET is expressed 
as milli BRET units (mBU) and is given as the mean ± SEM of 8 different experiments grouped by amount of BRET acceptor. 
A closer inspection using bioluminescence resonance energy transfer (BRET) showed 
a saturation curve, thus confirming the formation of complexes of A2AR-Rluc and CB1R-
YFP (BRETmax = 37 ± 2; BRET50 = 17 ± 4), and a lack of effect of methamphetamine (BRETmax 
= 39 ± 3; BRET50 = 22 ± 9). A linear relationship was found for the negative control per-
formed using plasmids encoding for receptors that do not heteromerize, D1R-Rluc and 
CB1R-YFP (Figure 1G). 
2.2. Methamphetamine Blocks CB1R Function in HEK-293T Cells Expressing the A2A–CB1Het 
HEK-293T cells transfected with the cDNA for A2A and CB1 receptors, i.e., expressing 
heteromers formed by the two receptors (A2A–CB1Hets), were pre-treated with selective 
antagonists (SCH 58261 for A2AR or SR 141716A for CB1R) prior to treatment with selective 
agonists (CGS 21680 for A2AR and/or arachidonyl-2′-chloroethylamide -ACEA- for CB1R) 
and the following signaling outputs were analyzed: cytosolic cAMP and Ca2+ level deter-
mination, ERK1/2 and Akt phosphorylation, β-arrestin 2 recruitment and dynamic mass 
redistribution (DMR). 
Figure 1. The effect of methamphetamine on A2AR–CB1R colocalization and receptor–receptor interaction. Confocal
microscopy images were obtained in HEK-293T cells transfected with 0.5 µg cDNA coding for CB1R-YFP (A,D), with 0.5 µg
cDNA for A2AR-Rluc (B,E) or with 0.5 µg cDNA for both CB1R-YFP and A2AR-Rluc (C,F). Cells were treated with 1 µM
methamphetamine (D–F) or vehicle (A–C) for 1 h. Receptors fused to Rluc (red) were identified by immunocytochemistry
and receptors fused to YFP (green) were identified by their own fluorescence. Colocalization is shown in yellow. Nuclei
were stained with Hoechst (blue). Images are taken near the surface of the slide to observe a higher portion of the plasma
membrane. Scale bars: 20 µm. (G): Bioluminesc n Resonance Energy Transfer (BRET) assays were performed in HEK-293T
cells transfected with a const nt amount of the cDNA oding f r A2AR fused to Rluc (1 µg) or the cDNA oding f r D1R
fused to Rluc (0.5 µg to 4.5 µg) (red lin ) and increasing mounts of the cDNA coding for CB1R fused to YFP (0.5 µg to
4.5 µg). Transfected cells were treated (green dots) or not (blue dots) with 1 µM methamphetamine. BRET is expressed as
milli BRET units (mBU) and is given as the mean ± SEM of 8 different experiments grouped by amount of BRET acceptor.
A closer inspection using bioluminescence resonance energy transfer (BRET) showed
a saturation curve, thus confirming the formation of complex s of A2AR-Rluc and CB1R-
YFP (BRETmax 37 ± 2; BRET50 = 17 ± 4), and a lack of effect of meth phetamine
(BRETmax = 39 ± 3; BRET50 = 22 ± 9). A linear relationship was fou d for the negativ
control performed using plasmids encoding f r receptors that do n t heteromerize, D1R-
Rluc and CB1R-YFP (Figure 1G).
2.2. Methamphetamine Blocks CB1R Function in HEK-293T Cells Expressing the A2A–CB1Het
HEK-293T cells transfected with the cDNA for A2A and CB1 receptors, i.e., expressing
heteromers formed by the two receptors (A2 –CB1Hets), were pre-treated with selective
antagonists (SCH 58261 for A2AR or SR 141716A for CB1R) prior to treatment with selec-
tive agonists (CGS 21680 for A2AR and/or arachidonyl-2′-chloroethylamide -ACEA- for
CB1R) and the following signaling outputs were analyzed: cytosolic cAMP and Ca2+ level
determination, ERK1/2 and Akt phosphorylation, β-arrestin 2 recruitment and dynamic
mass redistribution (DMR).
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Due to A2AR coupling to the Gs protein, which activates adenylyl cyclase, and CB1R
coupling to the Gi protein, which inhibits adenylate cyclase, we analyzed the effect of
agonists, alone or in combination, in naïve cells and in cells pretreated with forskolin
(0.5 µM, 15 min, FK), the activator of the adenylyl cyclase. The A2AR agonist, CGS 21680,
induced a significant increase in cAMP (around 3-fold compared to basal condition), while
treatment with the CB1R agonist, ACEA, induced a significant decrease over forskolin
cAMP level increases (Figure 2A). These results indicate that both A2AR and CB1R can be
activated when forming A2AR–CB1R complexes and are able to couple to their respective
cognate G proteins. An often-found feature of heteromers is cross-antagonism, i.e., the
antagonist of one receptor also blocks the signal mediated by the partner receptor within the
heteromer. When cotransfected cells were pre-treated with the selective antagonists before
agonist stimulation, it was observed that the A2AR antagonist counteracted A2AR signaling,
while it had a slight effect over CB1R activation. A qualitatively similar result was obtained
using the CB1R antagonist, i.e., blockade of activation of the cognate receptor, CB1R, but not
of A2AR activation (Figure 2A). When a similar experiment was undertaken in cells treated
for 1 h with methamphetamine before stimulation with selective agonists, CB1R signaling
was negligible (Figure 2B). After methamphetamine action, cross-antagonism was still
undetectable. It should be noted that ACEA does not affect basal cAMP production and
that, at the concentration used, CGS does not affect forskolin-induced cAMP production.
In cells expressing A2A–CB1Hets, both agonists, CGS 21680 and ACEA, increased
ERK1/2 and Akt phosphorylation. Moreover, when the same cells were simultaneously
coactivated with both agonists, the effect was lower than the sum of individual effects at
the same ligand concentration (Figure 2C,E). Interestingly, the A2AR antagonist not only
blocked the CGS 21680- but also the ACEA-induced effect. Such cross-antagonism was also
detected when cells were treated with the selective CB1R antagonist. Under the same assay
conditions, pretreatment with methamphetamine completely blocked CB1R function and
decreased A2AR-mediated function (Figure 2D,F).
After receptor activation, most GPCRs recruit β-arrestin before internalization. Inter-
estingly, when analyzing β-arrestin recruitment in HEK-293T cells coexpressing A2AR and
CB1R, it was observed that recruitment was very small (Figure 3A). However, β-arrestin
recruitment was potentiated in cells pretreated with methamphetamine (Figure 3B).
Dynamic mass redistribution (DMR) is a technique that allows detection of G protein-
mediated signaling in living cells by measuring cytoskeleton movements derived from
receptor activation [27–30]. Selective agonists led to a significant signal although simul-
taneous treatment with agonists did not lead to summation of effects. The use of the
output signal in the presence of antagonists underscored cross-antagonism (Figure 3C).
Analysis by DMR of A2AR activation showed that it was partially inhibited by metham-
phetamine pre-treatment, while CB1R activation was completely blocked by the drug of
abuse (Figure 3D).
In agreement with A2AR coupling to Gs and CB1R coupling to Gi protein, neither
activation of A2AR, nor of CB1R led to significant alterations in cytoplasmic Ca2+ levels
(Figure 3E). Although some drugs are able to produce a shift in the G protein-coupled
to a given GPCR, methamphetamine did not promote Gq coupling to A2AR or to CB1R
receptors (Figure 3F).
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Figure 2. Methamphetamine effect on A2A–CB1Het functionality: cAMP and ERK/Akt phosphory-
lation. HEK-293T cells co-transfected with cDNAs for A2AR (0.5 μg) and for CB1R (0.6 μg) were 
treated (30 min) with vehicle (A,C,E) or 1 μM methamphetamine (B,D,F) and subsequently treated 
with 500 nM of the A2AR antagonist SCH 58261 (SCH) or with 500 nM of the CB1R antagonist SR 
141716A (SR). Receptors were activated using 100 nM of the A2AR agonist CGS 21680 (CGS), with 
200 nM of the CB1R agonist, ACEA or both, before adding 0.5 μM forskolin (FK) or vehicle. The 
cytosolic cAMP levels (A,B) and the extracellular signal-regulated (ERK) 1/2 (C,D) or Akt (E,F) 
phosphorylation signals were determined. Results are expressed as percentage over basal and are 
the mean ± SEM of six experiments performed in triplicates. A one-way ANOVA followed by Bon-
ferroni multiple comparison post hoc test showed a significant effect (* p < 0.05, ** p < 0.01, *** p < 
0.001 vs. basal condition; ### p < 0.001 vs. FK condition). In (C–F) a representative Western blot is 
shown (bottom). p-ERK indicates phosphorylated ERKs, t-ERK indicates total ERKs, p-AKT indi-
cates phosphorylated AKTs. 
Figure 2. Methamphetamine effect on A2A–CB1Het functionality: cAMP and ERK/Akt phospho-
rylation. HEK-293T cells co-transfected with cDNAs for A2AR (0.5 µg) and for CB1R (0.6 µg) were
treated (30 min) with vehicle (A,C,E) or 1 µM methamphetamine (B,D,F) and subsequently treated
with 500 nM of the A2AR antagonist SCH 58261 (SCH) or with 500 nM of the CB1R antagonist SR
141716A (SR). Receptors were activated using 100 nM of the A2AR agonist CGS 21680 (CGS), with
200 nM of the CB1R agonist, ACEA or both, before adding 0.5 µM forskolin (FK) or vehicle. The
cytosolic cAMP levels (A,B) and the extracellul r s gnal-regulated (ERK) 1/2 (C,D) or Akt (E,F)
phosphorylation signals were determined. Results re xpressed as percentage over basal and are
the mean ± SEM of six experiments performed in triplicates. A one-way ANOVA followed by
Bonferroni multiple comparison post hoc test showed a significant effect (* p < 0.05, ** p < 0.01,
*** p < 0.001 vs. basal condition; ### p < 0.001 vs. FK condition). In (C–F) a representative Western
blot is shown (bottom). p-ERK indicates phosphorylated ERKs, t-ERK indicates total ERKs, p-AKT
indicates phosphorylated AKTs.
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Figure 3. Methamphetamine effect on A2A–CB1Het functionality: ß-arrestin-2 recruitment, dynamic 
mass redistribution (DMR) and Ca2+ mobilization. HEK-293T cells transfected with cDNAs corre-
sponding to A2AR-YFP (0.4 μg), CB1R (0.3 μg) and ß-arrestin-2-Rluc (0.5 μg) (A,B) or with A2AR (0.5 
μg), CB1R (0.6 μg) (C,D) and 6GCaMP calcium sensor (1.5 μg) (E,F) were treated (30 min) with 
vehicle (A,C,E) or with 1 μM methamphetamine (B,D,F) and subsequently treated with 500 nM of 
the A2AR antagonist SCH 58261 (SCH) or with 500 nM of the CB1R antagonist SR 141716A (SR). 
Receptors were activated using 100 nM of the A2AR agonist CGS 21680 (CGS), with 200 nM of the 
CB1R agonist ACEA or both. In (E,F), a portion of the cells were stimulated with 1 μM ionomycin 
as a positive control. The BRET data resulting from ß-arrestin-2 recruitment (A,B), time-dependent 
DMR representative traces (C,D) and time-dependent representative traces of cytoplasmic Ca2+ 
levels (E,F) are shown. In A,B, BRET is expressed as milli BRET units (mBU) and is given as the 
mean ± SEM of six different experiments grouped by amount of BRET acceptor. A one-way 
ANOVA followed by Bonferroni multiple comparison post hoc test showed a significant effect 
over 100% (& p < 0.05, &&& p < 0.001 versus ACEA condition; %% p < 0.01 versus CGS condition). 
  
Figure 3. Methamphetamine effect on A2A–CB1Het functionality: ß-arrestin-2 recruitment, dynamic
mass redistribution (DMR) and Ca2+ mobilization. HEK-293T cells transfected with cDNAs corre-
sponding to A2AR-YFP (0.4 µg), CB1R (0.3 µg) and ß-arrestin-2-Rluc (0.5 µg) (A,B) or with A2AR
(0.5 µg), CB1R (0.6 µg) (C,D) and 6GCaMP calcium sensor (1.5 µg) (E,F) were treated (30 min) with
vehicle (A,C,E) or with 1 µM methamphetamine (B,D,F) and subsequently treated with 500 nM of
the A2AR antagonist SCH 58261 (SCH) or with 500 nM of the CB1R antagonist SR 141716A (SR).
Receptors were activated using 100 nM of the A2AR agonist CGS 21680 (CGS), with 200 nM of the
CB1R agonist ACEA or both. In (E,F), a portion of the cells ere sti ulated ith 1 µ iono ycin as a
positive control. The BRET data resulting from ß-arrestin-2 recruitment (A,B), time-depend t DMR
representative traces (C,D) and time-dependent repres ntative traces of ytoplasmic Ca2+ levels (E,F)
are shown. In (A,B), BRET is expressed as milli BRET units (mBU) and is given as the mean ± SEM
of six different experiments grouped by amount of BRET acceptor. A one-way ANOVA followed
by Bonferroni multiple comparison post hoc test showed a significant effect over 100% (& p < 0.05,
&&& p < 0.001 vs. ACEA condition; %% p < 0.01 vs. CGS condition).
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2.3. Methamphetamine Action in Cells Expressing A2A or CB1 Receptors
It should be noted that the σ1R, which mediates the action of some drugs of abuse,
is endogenously expressed in HEK-293T cells [20,21,31,32]. Hence, we next addressed
the mechanisms by which methamphetamine alters signaling in cells expressing A2A or
CB1 receptors. We first analyzed data from HEK-293T cells expressing only the A2AR.
In cAMP level determination assays, the CGS 21680-induced increase in cAMP levels
was not affected by pretreatment with methamphetamine (Figure 4A). This result was
different from that observed in Figure 2A,B, where in HEK-293T cells expressing A2A–
CB1Hets, methamphetamine pretreatment partially blocked A2AR signaling. Data from
MAPK pathway activation shows that methamphetamine per se is able to activate this
signaling pathway; combined treatment of the drug of abuse and CGS 21680 resulted in an
additive-like response, i.e., the drug did not disrupted the link of A2AR activation to the
MAPK pathway (Figure 4B). Hence, it appears that the action of methamphetamine on the
A2AR depends on CB1R expression and, likely, on A2A–CB1Het expression.
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cells, over forskolin treatment. Values are the mean ± SEM (n = 5, in triplicates). One-way ANOVA followed by Bonferroni 
multiple comparison post hoc test showed a significant effect (* p < 0.05, *** p < 0.001 vs. basal condition, ### p < 0.001 
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Figure 4. σ1R involvement in methamphetamine effects on A2 and CB receptors. HEK-293T cells transfected with cDNAs
coding for A2AR (0.5 µg) (A,B) or for CB1 (0. µ ) ( , ) or presence (D,F) of siRNA for σ1R (3 µg)
to silence σ1R wer stimulated with 1 µM methamphetamine (Met, white bars) or vehicle (black bars) for 30 min. Cells were
treated with 100 nM of the A2AR agonist CGS 21680 (CGS) (A,B) or with 200 nM of the CB1R agonist, ACEA (C–F). 0.5 µM
of forskolin (FK) was used to determine Gi coupling to the CB1R. Then, cAMP levels (A,C,D) and ERK1/2 phosphorylation
(B,E,F) were determined and expressed as percentage over basal or, in the case of cAMP in CB2R-expressing cells, over
forskolin treatment. Values are the mean ± SEM (n = 5, in triplicates). One-way ANOVA followed by Bonferroni multiple
comparison post hoc test showed a significant effect (* p < 0.05, *** p < 0.001 vs. basal condition, ### p < 0.001 vs. FK
condition). In (B,E,F), a r presentative Western blot is shown (bottom). In (G), FRET experiments were performed in
HEK-293T cells transfected with 0.25 µg of cDNA for σ1R-YFP and increasing amounts of cDNA for CB1R-RFP (0.2 µg to
2 µg) or for A2AR-RFP (0.1 µg to 1.5 µg). When indicated cells were pretreated with 1 µM methamphetamine. Results were
grouped by amount of FRET acceptor. p-ERK indicates phosphorylated ERKs, t-ERK indicates total ERKs.
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In contrast, the effect of methamphetamine on CB1R-mediated signaling is not de-
pendent on A2AR expression. In fact, ACEA effects on forskolin-induced increases of
cAMP levels (Figure 4C) and on MAPK pathway activation (Figure 4E) were blocked
by methamphetamine. To further explain the mechanism by which methamphetamine
may block CB1R action, we focused on the σ1 receptor (σ1R), which is a transmembrane
receptor that does not belong to the GPCR family. It is a target of cocaine and its func-
tionality in rodents is altered upon methamphetamine treatment [22,26,33]. Interestingly,
the methamphetamine blockade of CB1R signaling was mediated by the σ1R as it dis-
appeared when a siRNA designed for σ1R silencing was used (Figure 4D,F). In terms
of ERK phosphorylation, the methamphetamine action was not further increased by the
activation of the CB1R (Figure 4E). However, a summation effect was obtained in cells
in which the σ1R was silenced (Figure 4F). Altogether, the results suggest that the σ1R
mediates the inhibition of the CB1R to the MAPK and cAMP pathways exerted by metham-
phetamine and that σ1R and CB1R could physically interact. We performed fluorescence
resonance energy transfer (FRET) assays using cells expressing a constant amount of cDNA
for σ1R-YFP and increasing amounts of cDNA for CB1R-RFP. The interaction is possible as
deduced from the saturation curve (Figure 4G). FRET parameters were: FRETmax = 17 ± 1
and FRET50 = 19 ± 5. The interaction was maintained in cells pretreated with metham-
phetamine although with a significant alteration in FRET parameters (FRETmax = 23 ± 3,
FRET50 = 10 ± 5). On the one hand, these results indicate that the drug produces an in-
crease in CB1R-σ1R complexes or a structural reorganization leading to an approximation
of the two fluorescent proteins. On the other hand, in agreement with the lack of effect of
methamphetamine on the A2AR when the CB1R is not present, FRET assays showed a linear
nonspecific signal, i.e., a lack of interaction between σ1R-YFP and A2AR-RFP (Figure 4G,
red line).
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pretreatment. Therefore, alteration of A2AR-mediated signaling is dependent upon CB1R
expression and A2A–CB1 receptor heteromerization (Figure 5). Furthermore, the σ1R was
required as the effect of the drug on A2AR-mediated signaling disappeared in cells in
which the σ1R was silenced (Figure 5B) but not in cells treated with a siRNA designed for
calneuron-1 silencing (Figure 5C). These results suggest that a functional complex formed
by the three receptors is expressed in these cells. In contrast, the results obtained using the
agonist of the CB1R were similar to those found in cells only expressing the cannabinoid
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RFP. Saturation of the SRET curve (Figure 5G) indicates that the three proteins interact (the
dopamine D1 receptor was used as a negative control). The SRET signal did not significantly
change upon treatment with methamphetamine (SRETmax = 21 ± 2 and SRET50 = 34 ± 12
in the absence of the drug and SRETmax = 25 ± 3 and SRET50 = 24 ±10 in the presence of
methamphetamine). As the A2AR is unable to interact with σ1R (Figure 4G), it is hypothe-
sized that the trimer is formed by the CB1R ability to bind to both A2AR and σ1R.
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per cell expressing dots) and even more after the chronic regime (84% of neurons expressing 
red dots and around 13 red dots per cell expressing dots) (Figure 6A,B). 
2.6. Blockade by Methamphetamine of CB1R–A2AR Complex Signaling in Striatal Neurons 
First, in signaling assays performed in striatal neurons, the A2A–CB1Het print, namely 
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PLA experiments were also performed in striatal neurons treated with 1 µM metham-
phetamine for two hours (acute) or for one week (chronic). On the one hand, the drug
in either acute or chronic treatment did not affect the expression of A2AR–CB1R and of
A2AR–σ1R c mplexes. On the other hand, the expression of CB1R–σ1R complexes was
significantly increased upon acute tre tment (76% of neurons expressing red dots a d
around 10 red dots per cell expressing dots) and even more after the chronic regime (84% of
neurons expressing red dots and around 13 red dots per cell expressing dots) (Figure 6A,B).
2.6. Blockade by Methamphetamine of CB1R–A2AR Complex Signaling in Striatal Neurons
First, in signaling assays performed in striatal neurons, the A2A–CB1Het print, namely
cross-antagonism, was detected (Figure 6). In addition, the non-additive effect observed
in the heterologous expression system was detected (Figure 6). After demonstrating
A2A–CB1Het expression by PLA (see previous section) and by detection of the heteromer
print, further assays were performed to evaluate how methamphetamine may affect signal-
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ing in these cells. Primary cultures of striatal neurons were treated for two hours (acute)
or for one week (chronic) with methamphetamine prior to assessing the effect of A2AR or
CB1R agonists on cAMP levels and MAPK pathway activation. Interestingly, it was first
observed that ACEA-induced decreases of cAMP levels were partially inhibited by acute
and chronic methamphetamine treatments (Figure 6C), while ERK1/2 phosphorylation
was completely blocked (Figure 6D). Similarly, CGS 21680-induced increases in cAMP
levels were partially blocked after acute and chronic methamphetamine treatments, while
ERK1/2 phosphorylation was completely blunted (Figure 6C,D). These results show that
the drug, likely via interaction with σ1R in a heteromer context, partially reduces G-protein-
mediated signaling while completely abolishing MAPK pathway activation. Interestingly,
the effect on A2AR signaling to the MAPK pathway did not occur in the presence of a
CB1R antagonist.
3. Discussion
Cannabinoids and adenosine are two important neuromodulators in the central ner-
vous system (CNS). Two of their receptors have attracted interest due to their potential as
therapeutic targets. On the one hand, the CB1R is, reportedly, the most abundant GPCR
in the CNS and is mainly expressed in neurons [36–38]. Its potential is limited as some
of their agonists, such as the natural Cannabis sativa-derived compound ∆9-THC, lead
to psychotropic effects, while its antagonists may have serious side effects [39]. On the
other hand, the A2AR receptor is heavily expressed in the brain striatum where it regu-
lates dopamine neurotransmission. In addition, (i) it is expressed in other brain areas, in
both neurons and glia [40], and (ii) there is cumulative evidence of its participation in
neurodegenerative/neuroprotection events. Importantly, a first in class A2AR antagonist,
istradefylline, has been approved for the therapy of Parkinson’s disease (NouriastTM in
Japan and NourianzTM in the USA) [41–46]. This approval puts the A2AR on the front line
to combat neurodegeneration and/or to afford neuroprotection.
The mechanisms of neurodegeneration due to methamphetamine consumption are
not well understood yet. It should be noted that the σ1R is a common factor in cocaine and
methamphetamine addiction [26]. It is well established that cocaine binds to this atypical
transmembrane receptor, which is structurally different to GPCRs, occurs as a homotrimer
and has no known endogenous agonist [47–49]. In animals treated with methamphetamine,
the alterations involve σ1R-mediated events. About 15 years ago it was reported that
locomotor effects of the drug could be reverted if animals were administered antisense
probes that reduced the expression of the σ1R receptor in the brain; similar results were
obtained using the commercially available antagonists [22]. Our first hypothesis, namely
that the σ1R could interact with the A2AR and mediate effects of the drug on the receptor
was not proven. Not only did the two receptors not interact, but methamphetamine did
not directly affect A2AR functionality. However, CB1R is required for methamphetamine
altering A2AR signaling.
Previous experience has shown us that the σ1R may interact with GPCRs to form
complexes that mediate some of the relevant central effects exerted by cocaine. For instance,
an interaction between σ1, orexin and corticotropin-releasing factor receptors are the target
of cocaine in the ventral tegmental area [50]. Remarkably, the anorexic effect of cocaine
is, at least in part, due to the formation of a complex between the σ1R and the ghrelin
receptor that allows the blockade of ghrelin action [31]. Our next hypothesis was then to
consider interactions of the σ1R with GPCR heteromers, whose functionality is different
from that exerted by individual receptors [51–53]. In fact, biased signaling may be achieved
by GPCR heteromers and/or by complexes formed by GPCRs and other proteins [54]. We
here demonstrate that σ1R may interact with the CB1R so that σ1R, CB1R and A2AR may
form trimers.
Although the A2AR may interact with several other GPCRs (see www.gpcr-hetnet.
com/, accessed on 7 March 2021), we were interested in interactions with the receptors of
cannabinoids and, in particular, with the most abundant GPCR among CNS neurons, the
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CB1R. Actually, the interaction of these two GPCRs in an heterologous expression system
and, among others, in the striatum and in CA1 neurons in the hippocampus, has been
reported [10,16,55–58]. Then, we aimed at finding whether the σ1R could interact with
the CB1R and, upon confirming this possibility, whether methamphetamine acting on σ1R
could alter A2AR-mediated signaling via the A2A–CB1Het. The results not only confirmed
the hypothesis but showed a strong effect upon the A2AR in co-transfected HEK-293 cells
and in primary cultures of striatal neurons. Alterations by the drug in cAMP-dependent
signaling are important but less than those in the MAPK pathway. In fact, the A2A–CB1Het
is coupled to both Gs and Gi and both are altered, thus leading to a counterbalancing
effect. In contrast, the effect of the drug on the MAPK pathway was in the same direction
for both receptors, i.e., blocking the activation of the pathway. In addition, the results
indicate that methamphetamine acts on a functional unit formed by the three receptors but
with the A2AR being unable to bind to σ1R and with the CB1R able to bind both σ1 and
A2A receptors.
In summary, methamphetamine alters A2AR-mediated signaling in striatal neurons but
only if the CB1R is present and the A2A–CB1Het is expressed. Failure to properly activate
the MAPK signaling pathway in neurons unrolls the neurodegenerative mechanism due to
the lack of those transcription factors that favor the expression of neuroprotective molecules
(see [59] for review).
4. Materials and Methods
4.1. Reagents
Forskolin and receptor ligands CGS 21680 hydrochloride, ACEA, SCH 58261 and SR
141716A were purchased from Tocris Bioscience (Bristol, UK). Ionomycin and metham-
phetamine hydrochloride were purchased from MERK (St. Louis, MO, USA). siRNAs were
purchased from ThermoFisher Scientific (Waltham, MA, USA).
4.2. Expression Vectors
cDNAs for the human version of cannabinoid CB1, adenosine A2A, dopamine D1
and σ1 receptors without the stop codon were obtained by PCR and subcloned to a Rluc-
containing vector (pRluc-N1; PerkinElmer, Wellesley, MA, USA), to an enhanced yellow
fluorescent protein-containing vector (pEYEP-N1; Clontech, Heidelberg, Germany) or to
a cherry (RFP)-containing vector (pcDNA 3.1 Cherry) using sense and antisense primers
harboring unique restriction sites for HindIII and BamHI to generate A2AR-Rluc, D1R-
Rluc, CB1R-YFP, D1R-YFP, A2AR-RFP and CB1R-RFP or for BamHI and KpnI to generate
σ1R-Rluc and σ1R-YFP fusion proteins.
4.3. Cell Culture and Transfection
HEK-293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 2 mM L-glutamine, 100 U/mL penicillin/streptomycin, MEM Non-Essential
Amino Acids Solution (1/100) and 5% (v/v) heat inactivated fetal bovine serum (FBS)
(all from Gibco, Paisley, Scotland, UK). Cells were maintained in a humid atmosphere
of 5% CO2 at 37 ◦C and were passaged when they were 80–90% confluent (number
of passages < 18). Cells were transiently transfected with the corresponding cDNAs
using the Polyethylenimine (PEI) (MERK, St. Louis, MO, USA) method as previously
described [28,60] or with siRNA using the lipofectamine 2000 (ThermoFisher Scientific,
Waltham, MA, USA) method following the instructions of the supplier cells were incubated
with transfection reagents in serum-free medium; 4 h later the medium was replaced by
complete medium. Experiments were carried out 48 h later.
To prepare mouse neuronal primary cultures, striatum from embryos (E19) was
removed and neurons were isolated as described by Hradsky et al., 2013 [61]. In brief,
striatum was digested with trypsin for 15 min at 37 ◦C. Trypsinization was stopped by
several washes with HBSS (137 mM NaCl, 5 mM KCl, 0.34 mM Na2HPO4, 0.44 mM
KH2PO4, 1.26 mM CaCl2, 0.4 mM MgSO4, 10 mM HEPES pH 7.4). Cells were brought to a
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homogeneous suspension by passage through 0.9 mm and 0.5 mm needles and through a
100 µm-pore mesh. Finally, cells were grown in neurobasal medium supplemented with
2 mM L-glutamine, 100 U/mL penicillin/streptomycin, MEM Non-Essential Amino Acids
Solution (1/100) (all from Invitrogen, Paisley, Scotland, UK) and 2% (v/v) B27 supplement
(Gibco, Paisley, Scotland, UK) for 12 days. For cAMP assays, cells were grown on 6-well
plates at a density of 500,000 cells/well, for ERK 1/2 phosphorylation assays, cells were
plated in 96-well plates at a density of 50,000 cells/well and for the proximity ligation
assay, neurons were plated in coverslips in 12-well plates at a density of 100,000 cell/well.
Cell counting was assessed using trypan blue and a countless II FL automated cell counter
(ThermoFisher Scientific, Waltham, MA, USA).
The animal handling and protocols were conducted in accordance with the European
Council Directive 2010/63/UE and the current Spanish legislation (RD53/2013). The ethics
committee of the University of Barcelona were in charge of law implementation.
4.4. Immunocytochemistry
HEK-293T cells expressing A2AR-Rluc and/or CB1R-YFP seeded in coverslips were
treated for one hour with vehicle or 1 µM methamphetamine, fixed in 4% paraformaldehyde
for 15 min and washed twice with phosphate-buffered saline (PBS) containing 20 mM
glycine to quench the aldehyde groups before permeabilization with PBS-glycine containing
0.2% Triton X-100 (5 min). Cells were treated for 1 h with PBS containing 1% bovine
serum albumin (BSA), labelled with a primary mouse monoclonal anti-Rluc (1/100; EMD
Millipore, Darmstadt, Germany, Ref. MAB4400) antibody for 1 h, and subsequently treated
for 1 h with an anti-mouse Cy3-conjugated IgG (red) (1/200; Jackson Immuno Research,
West Grove, PA, USA, Ref. 715-166-150) antibody. Nuclei were stained with Hoechst
(1/100; MERK, St. Louis, MO, USA, Ref. B1155). Samples were washed several times and
mounted with 30% Mowiol (Calbiochem, San Diego, CA, USA). CB1R-YFP expression was
detected by YFP own fluorescence (green). Images were obtained in a Leica SP2 confocal
microscope (Leica Microsystems, Mannheim, Germany) equipped with an apochromatic
63X oil-immersion objective (N.A. 1.4), and 405 nm, 488 nm and 561 nm laser lines.
4.5. Resonance Energy Transfer Assays
For bioluminescence resonance energy transfer (BRET) assays, HEK-293T cells were
transiently co-transfected with constant amount of cDNAs encoding for receptor-Rluc
fusion proteins and increasing amounts of cDNAs corresponding to receptor-YFP fusion
proteins. Forty-eight hours post-transection, cells were detached using 0.1% glucose HBSS
buffer and the cell suspension was adjusted to 20 µg/µL of protein using a Bradford
assay kit (Bio-Rad, Munich, Germany) and BSA for standardization. Cells were treated
with 1 µM methamphetamine or vehicle 1 h prior to each quantification. To quantify
protein-YFP expression, cells were distributed in 96-well black plates with a clear bottom
(Porvair, Wrexham, Wales, UK) and fluorescence was read in a Mithras LB 940 (Berthold
Technologies, Bad Wildbad, Germany) equipped with a high-energy xenon flash lamp,
using a 10-nm bandwidth excitation filter at 485 nm and 530 nm emission filter readings.
For BRET measurements, cells were distributed in 96-well white plates with a clear bottom
(Porvair) and readings were collected 1 min after the addition of 5 µM coelenterazine
H (PJK GMBH, Kleinblittersdorf, Germany) using a Mithras LB 940, which allows the
integration of the signals detected in the short-wavelength filter at 485 nm and the long-
wavelength filter at 530 nm. To quantify protein-Rluc expression, luminescence readings
were performed 10 min after 5 µM coelenterazine H addition using a Mithras LB 940 reader.
For fluorescence resonance energy transfer (FRET) assays, HEK-293T cells were tran-
siently co-transfected with a constant amount of cDNAs encoding for receptor-YFP and
increasing amounts of cDNAs corresponding to receptor-Cherry (RFP). Forty-eight hours
after transfection, cells were detached using HBSS buffer with 0.1% glucose and cell sus-
pension was adjusted to 20 µg/µL of protein using a Bradford assay kit (Bio-Rad, Munich,
Germany) and bovine serum albumin (BSA) for standardization. Cells were treated with
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1 µM methamphetamine or vehicle 1 h prior to each quantification. Cells were distributed
in 96-well black plates with a clear bottom (Porvair). To quantify protein-YFP expression
and protein-cherry expression, fluorescence was red in a FluoStar Optima Fluorimeter
(BMG Labtechnologies, Offenburg, Germany) equipped with a high-energy xenon flash
lamp, using a 10-nm bandwidth excitation filters at 485 nm (for YFP) and 540 nm (for
RFP) and emission filters at 530 nm (for YFP) and 590 nm (for Cherry) readings. For FRET
measurements, fluorescence was read in a FluoStar Optima Fluorimeter equipped with a
high-energy xenon flash lamp, which allows the integration of the signals detected in the
short-wavelength filter at 530 nm and the long-wavelength filter at 590 nm.
Net BRET and net FRET were defined as [(long-wavelength emission)/(short-wavelength
emission)] − Cf where Cf corresponds to [(long-wavelength emission)/(short-wavelength
emission)] for the donor construct expressed alone in the same experiment (Rluc for BRET
and YFP for FRET). The GraphPad Prism software (San Diego, CA, USA) was used to fit
the data. BRET and FRET are expressed as milli BRET units, mBU (net BRET × 1000) or
milli FRET units, mFU (net FRET × 1000), respectively. The relative amount of BRET or
FRET is given as a function of 1000 × the ratio between the fluorescence of the acceptor
(YFP for BRET or Cherry for FRET) and the activity of the donor (Rluc for BRET or YFP
for FRET).
For sequential resonance energy transfer (SRET) assays (see [12]), HEK-293T cells
were transiently co-transfected with constant amounts of cDNA coding for the BRET
donor (receptor-Rluc), the first acceptor (receptor-YFP) and increasing amounts of cDNA
corresponding to the second acceptor (receptor-RFP). After 48 h, cells were detached using
HBSS buffer with 0.1% glucose and cell suspension was adjusted to 20 µg/µL of protein
using a Bradford assay kit (Bio-Rad, Munich, Germany) and bovine serum albumin (BSA)
for standardization. Cells were treated with 1 µM methamphetamine or vehicle 1 h prior to
each quantification. To quantify protein-RFP expression, fluorescence was read in a FluoStar
Optima Fluorimeter (BMG Labtechnologies) using a 10-nm bandwidth excitation filter at
540 nm and an emission filter at 590 nm. Receptor fluorescence expression was determined
as the fluorescence of the sample minus the fluorescence of cells expressing only receptor-
Rluc and receptor-YFP. To quantify receptor-Rluc expression, luminescence readings were
performed 10 min after 5 µM coelenterazine H addition using a Mithras LB 94 reader
(Berthold Technologies). For SRET measurements, the cell suspension was treated with
5 µM coelenterazine H for 1 min and the SRET signal was determined using a Mithras LB
940 reader (485 nm) (short wavelength emission) and FluoStar Optima Fluorimeter (590 nm)
(long wavelength emission). Net SRET was defined as [(long wavelength emission)/(short
wavelength emission)] − Cf, where Cf corresponds to long wavelength emission/short
wavelength emission for cells expressing only protein-Rluc and protein-YFP. SRET curves
were fitted assuming a single phase by non-linear regression equation using the Graphpad
Prism software (San Diego, CA, USA). SRET values are given as milli SRET units (mSU:
1000 × net SRET). The relative amount of SRET is given as a function of 1000 × the
ratio between the fluorescence of the FRET acceptor (RFP) and the activity of the BRET
donor (Rluc).
4.6. Cytosolic cAMP Determination
HEK-293T cells were transfected with the cDNA encoding for A2AR and/or for CB1R,
and when indicated, with the siRNA for σ1R or for caln-1. Neuronal primary cultures
were pretreated with 1 µM methamphetamine or vehicle for 2 h (acute treatment) or for
one week (chronic treatment). Transfected HEK-293T cells were pretreated (20 min) with
1 µM methamphetamine or vehicle. Two hours before initiating the experiment, culture
medium for transfected HEK-293T or primary neurons was replaced by serum-starved
DMEM medium. Cells were detached, resuspended in DMEM medium containing 50 µM
zardaverine (Tocris Bioscience, Bristol, UK) and plated (4000 cells/well) in white ProxiPlate
384-well microplates (PerkinElmer, Waltham, MA, USA). HEK-293T cells or neurons were
treated with the corresponding antagonists (SCH 58261 for A2AR or SR 141716A for CB1R)
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or vehicle and stimulated (15 min) with the corresponding agonists (CGS 21680 for A2AR
and/or ACEA for CB1R) or vehicle before adding 0.5 µM forskolin (15 min). Readings
were performed after 1-h incubation at room temperature. Homogeneous time-resolved
fluorescence energy transfer (HTRF) measurements were performed using the Lance Ultra
cAMP kit (PerkinElmer, Waltham, MA, USA). Fluorescence at 665 nm was analyzed on a
PHERAstar Flagship microplate reader equipped with an HTRF optical module (BMG Lab
technologies, Offenburg, Germany). The effect of ligands was given in percentage with
respect to the reference value.
4.7. Extracellular Signal-Regulated Kinase (ERK) and Protein Kinase B (Akt) Phosphorylation
Assays
HEK-293T cells were transfected with the cDNA encoding for A2AR and/or for CB1R,
and when indicated, with the siRNA of σ1R. Two to four hours before initiating the
experiment, the culture medium was replaced by serum-starved DMEM medium. Cells
were incubated at 37 ◦C with 1 µM methamphetamine (30 min) or vehicle, followed with
the corresponding antagonist (SCH 58261 for A2AR or SR 141716A for CB1R) (20 min) and
stimulated (7 min) with the corresponding agonists (CGS 21680 for A2AR and/or ACEA for
CB1R). After the indicated incubation period, the reaction was stopped by placing cells onto
ice. Then, cells were washed twice with cold PBS and lysed by the addition of ice-cold lysis
buffer (50 mM Tris-HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM ß-glycerolphosphate,
1% Triton X-100, 20 µM phenyl-arsine oxide, 0.4 mM NaVO4 and protease inhibitor mixture
(MERK, St. Louis, MO, USA)). Cellular debris were removed by centrifugation at 13,000× g
for 10 min at 4 ◦C, and protein was adjusted to 1 mg/mL by the bicinchoninic acid method
(ThermoFisher Scientific, Waltham, MA, USA) using a commercial bovine serum albumin
dilution (BSA) (ThermoFisher Scientific) for standardization. Finally, cells were denatured
by placing them at 100 ◦C for 5 min. Akt and ERK1/2 phosphorylation were determined
by western blot. Equivalent amounts of protein (20 µg) were subjected to electrophoresis
(10% SDS-polyacrylamide gel) and transferred onto PVDF membranes (Immobilon-FL
PVDF membrane, MERK, St. Louis, MO, USA) for 90 min. Then, the membranes were
blocked for 1 h at room temperature (constant shaking) with Odyssey Blocking Buffer
(LI-COR Biosciences, Lincoln, NE, USA) and labelled with a mixture of primary mouse
anti-phospho-ERK 1/2 antibody (1:2000, MERK, Ref. M8159), primary rabbit anti-ERK 1/2
antibody (1:40,000, MERK, Ref. M5670), which recognizes both phosphorylated and non-
phosphorylated ERK 1/2, and primary rabbit anti-phosphoAkt antibody (1:2500, Signalway
Antibody, Baltimore, MA, USA, Ref. 11054) overnight at 4 ◦C with shaking. Then, the
membranes were washed three times with PBS containing 0.05% tween and visualized by
the addition of a mixture of IRDye 800 anti-mouse antibody (1:10,000, MERK, Ref. 926-
32210) and IRDye 680 anti-rabbit antibody (1:10,000, MERK, Ref. 926-68071) for 2 h at room
temperature. Membranes were washed 3 times with PBS-tween 0.05% and once with PBS
and left to dry. Bands were analyzed using Odyssey infrared scanner (LI-COR Biosciences).
Band densities were quantified using the scanner software, and the level of phosphorylated
ERK 1/2 and Akt was normalized using the total ERK 1/2 protein band intensities. Results
obtained are represented as the percent over basal (non-stimulated cells).
To determine the ERK 1/2 phosphorylation in striatal neuronal primary cultures,
50,000 neurons/well were plated in transparent 96-well microplates and kept in the incu-
bator for 12 days. Neurons were pretreated with 1 µM methamphetamine for 2 h (acute
treatment) or for one week (chronic treatment) or vehicle. Two to four hours before ini-
tiating the experiment, the medium was substituted by serum-starved DMEM medium.
Then, neurons were pre-treated at room temperature for 15 min with the specific antago-
nist (SCH 58261 for A2AR or SR141716A for CB1R) or vehicle, and finally stimulated for
10 min with the specific agonists (CGS 21680 for A2AR and/or ACEA for CB1R). Neurons
were then washed twice with cold PBS before the addition of 30 µL lysis buffer (20 min
treatment in constant agitation). Subsequently, 10 µL of each supernatant were placed in
white ProxiPlate 384-well microplates (PerkinElmer, Waltham, MA, USA) and the ERK
1/2 phosphorylation was determined using the AlphaScreen®SureFire® kit (PerkinElmer)
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following the instructions of the supplier and using an EnSpire® Multimode Plate Reader
(PerkinElmer). The effect of ligands is given as percentage over the reference values.
4.8. Dynamic Mass Redistribution (DMR) Assays
Cell mass redistribution induced upon receptor activation was detected by illuminat-
ing the underside of a biosensor with a polychromatic light and measuring the changes
in the wavelength of the reflected monochromatic light, which was a sensitive function
of the index of refraction. The magnitude of this wavelength shift (in picometers) was
directly proportional to the amount of dynamic mass redistribution (DMR). HEK-293T
cells co-transfected with the cDNA coding for A2AR and for CB1R were seeded in 384-well
sensor microplates (Corning® Epic® 384-well Cell Assay Microplate) (MERK, St. Louis, MO,
USA) to obtain a 70–80% confluent monolayer constituted by approximately 10,000 cells
per well. Before the assay, cells were washed twice with assay buffer (HBSS with 20 mM
HEPES pH 7.15 containing 0.1% DMSO) and maintained for 2 h at 24 ◦C in the same buffer
(30 µL/well). Then, the sensor plate was scanned, and a baseline optical signature was
recorded for 10 min before adding 10 µL of the specific antagonists (SCH 58261 for A2AR
or SR141716A for CB1R) in the presence or in the absence of 1 µM methamphetamine
and recorded for 30 min, followed by the addition of 10 µL of the specific agonists (CGS
21680 for A2AR and/or ACEA for CB1R) and monitoring for another 60 min. All of the
tested compounds were dissolved in the assay buffer. The cell signaling signature was
determined using an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA)
by a label-free technology. Results were analyzed using the EnSpire Workstation Software
v 4.10 (PerkinElmer).
4.9. Determination of Cytoplasmic Calcium Ion Levels
HEK-293T cells were co-transfected with the cDNAs coding for A2AR, CB1R and
GCaMP6 calcium sensor. At 48 h post-transfection, cells were detached using Mg2+ Locke’s
buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 2.3 mM CaCl2, 5.6 mM glucose and
5 mM HEPES, pH 7.4) supplemented with 10 µM glycine, and the cell suspension was
adjusted to 40 µg/µL of protein using a Bradford assay kit (Bio-Rad, Munich, Germany) and
BSA for standardization. Cells were plated in 96-well black with clear bottom microplates
(Porvair) and pretreated with 1 µM methamphetamine or vehicle for 1 h before treatment
with the specific antagonists (SCH 58261 for A2AR or SR 141716A for CB1R) for 10 min,
followed by the addition of the specific receptor agonists (CGS 21680 for A2AR and/or
ACEA for CB1R) or 1 µM ionomycin a few seconds before readings. Fluorescence emission
intensity of the GCaMP6 was recorded at 515 nm upon excitation at 488 nm on the EnSpire®
Multimode Plate Reader (PerkinElmer, Waltham, MA, USA) for 150 s every 5 s.
4.10. ß-Arrestin 2 Recruitment
HEK-293T cells were co-transfected with the cDNA coding for A2A-YFP, CB1R and
ß-arrestin 2-Rluc. At 48 h post-transection, cells were detached using 0.1% glucose HBSS
buffer and the cell suspension was adjusted to 30 µg/µL of protein using a Bradford assay
kit (Bio-Rad, Munich, Germany) and BSA for standardization. Cells were plated in 96-well
black with clear bottom plates (Porvair) and pretreated with 1 µM methamphetamine or
vehicle for 30 min before treatment with the specific antagonists (SCH 58261 for A2AR or
SR 141716A for CB1R) for 10 min. Coelenterazine H (5 µM) (PJK GMBH, Kleinblittersdorf,
Germany) was added before stimulation with the specific agonists (CGS 21680 for A2AR
and/or ACEA for CB1R) for 2 min. Then, BRET between ß-arrestin 2-Rluc and A2AR-YFP
was determined as described above (see Resonance Energy Transfer Assays).
4.11. Proximity Ligation Assays (PLA)
Striatal neuronal primary cultures grown on glass coverslips were pretreated with
1 µM methamphetamine for 2 h (acute treatment) or for one week (chronic treatment)
or vehicle. In brief, neurons were fixed in 4% paraformaldehyde for 15 min, washed
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with PBS containing 20 mM glycine to quench the aldehyde groups, and permeabilized
with the same buffer containing 0.05% Triton X-100 for 5 min. After 1 h incubation at
37 ◦C with blocking solution, the neurons were treated with specific antibodies against
A2A, CB1 or σ1 receptors. The following combinations of antibodies were used: mouse
monoclonal anti-A2AR (1/100, Santa Cruz Biotechnology, Dallas, Paisley, UK, Ref. 32261)
and rabbit polyclonal anti-CB1R (1/100; ThermoFisher Scientific, Waltham, MA, USA,
Ref. PA1-745), rabbit polyclonal anti-A2AR (1/100, ThermoFisher Scientific, Ref. PA1-042)
and mouse monoclonal anti-σ1R (1/100, Santa Cruz Biotechnology, Ref. 137075) or rabbit
polyclonal anti-CB1R (1/100, ThermoFisher Cientific) and mouse monoclonal anti-σ1R
(1/100, Santa Cruz Biotechnology). Cells were processed using the PLA probes detecting
mouse and rabbit antibodies (1/100, Duolink II PLA probe anti-rabbit plus and Duolink
II PLA probe anti-mouse, MERK, St. Louis, MO, USA) in the presence of Hoechst (1/100,
MERK). Preparations were mounted using 30% Mowiol (Calbiochem, San Diego, CA, USA).
Negative controls were performed by omitting one of the primary antibodies. Images were
obtained in a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany)
equipped with apochromatic 63X oil-immersion objectives (N.A. 1.4), and 405 and 561 nm
laser lines. For each field of view, a stack of two channels (one per staining) and 3 to 4 Z
stacks with a step size of 1 µm were acquired. The number of cells containing one or more
red spots versus total cells (blue nucleus) and, in spot-containing cells, the ratio r (number
of red spots/cell), were determined using the Duolink Image tool software (MERK).
4.12. Statistical Analysis
Graph data are the mean ± SEM (n = 6 at least). GraphPad Prism software version 8
(San Diego, CA, USA) was used for the data fitting and statistical analysis. A one-way or
two-way ANOVA followed by the post-hoc Bonferroni’s test were used when comparing
multiple values. Significant differences were considered when the p value was <0.05.
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A2AR Adenosine A2A receptor
BRET Bioluminescence Resonance Energy Transfer
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CB1R Cannabinoid CB1 receptor
CB2R Cannabinoid CB2 receptor
CGS CGS 21680
CNS Central nervous system
D1R Dopamine D1 receptor
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FRET Fluorescence Resonance Energy Transfer
HTRF Homogeneous time-resolved fluorescence energy transfer
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MAPK Mitogen activated protein kinase
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